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Preclinical studies suggest that dexamphetamine (dAMPH) can lead to monoaminergic neuro-
toxicity. This exploratory study aimed to investigate effects of recreational dAMPH use on the
dopamine (DA) and noradrenaline (NA) systems in humans. To that purpose, eight male abstinent
dAMPH (26.074.0 years) users and 10 age- and IQ-matched male healthy control subjects
(23.073.8) underwent neuropsychological testing sensitive to DAergic function and single photon
emission computed tomography (SPECT) scanning with [123I]FP-CIT to determine striatal DA
transporter (DAT) binding. In addition, changes in cerebral blood ﬂow (CBF) induced by the DA/NA
reuptake inhibitor methylphenidate (MPH) were measured using pharmacological magnetic
resonance imaging (phMRI). Performance of dAMPH users was signiﬁcantly worse on executive
function and verbal memory tasks. Striatal DAT binding ratios were on average lower in dAMPH
users (near-signiﬁcant, p=0.05). In addition, CBF in control subjects decreased signiﬁcantly in
response to MPH in gray matter and basal ganglia, among which the striatum, thalamus and
hippocampus by 10% to 29%. However, in dAMPH users the CBF response was blunted in most brain
areas studied, only decreasing in the hippocampus and orbitofrontal cortex. When comparing
groups, CBF response was found to be signiﬁcantly different in the thalamus with a decrease for
healthy controls and a blunted response in dAMPH users. Collectively, our ﬁndings of a blunted
hemodynamic response in monoaminergic regions, in combination with indications for lower
striatal DAT binding and poorer behavioral measures are likely to represent DAergic dysfunction in
dAMPH users, although NAergic dysfunction may also play a role.
& 2013 Elsevier B.V. and ECNP. All rights reserved.Elsevier B.V. and ECNP. All rights reserved.
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The dopaminergic (DAergic) system plays a pivotal role in
many different neurological and neuropsychiatric disorders,
such as Parkinson’s disease, schizophrenia and attention
deﬁcit hyperactivity disorder (ADHD) (for review (Missale
et al., 1998)). Consequently, many drugs have been
developed, that act on the dopamine transporter (DAT)
or dopamine receptors. Of these drugs, dexamphetamine
(dAMPH) is prescribed for the treatment of ADHD, but is also
frequently used in recreational settings. Preclinical studies
in non-human primates however, have indicated that even
clinically relevant doses of dAMPH can lead to damage of
nerve terminals of DAergic neurons: the concentration of
striatal DA, the DAT density and vesicular monoamine
transporter (VMAT-2) sites were signiﬁcantly reduced after
dAMPH administration (Ricaurte et al., 2005). Although
some positron emission tomography (PET) studies reported
loss of striatal DAT in methamphetamine (METH) users
(McCann et al., 1998, 2008), little is known about the
effects of recreational dAMPH use on the DA system in
human users. To our knowledge, only one study has pre-
viously investigated the effects of dAMPH in the human
brain. In this study reductions in striatal DAT binding were
observed using single photon emission computed tomography
(SPECT) (Reneman et al., 2002) in combined ecstasy and dAMPH
users versus sole ecstasy users. Because DA is involved in many
important neurobehavioral functions, such as executive and
motor function, attention and inhibition, it is important to
study the potential consequences of dAMPH-induced neurotoxi-
city (Van den Heuvel and Pasterkamp, 2008).
The purpose of the current study was to investigate the
effects of recreational dAMPH use on the DAergic system
using SPECT and a relatively novel MRI imaging technique,
called pharmacological MRI (phMRI), to assess DA (dys)func-
tion. phMRI indirectly determines monoaminergic function
by looking at the hemodynamic response to a pharmacolo-
gical challenge (Ogawa et al., 1990). Neurotransmitter-
speciﬁc drug challenges can evoke changes in synaptic
activity, and resultant alterations in metabolic demand,
requiring changes in cerebral blood ﬂow (CBF) and/or
cerebral blood volume (CBV) as a result of neurovascular
coupling (Jueptner and Weiller, 1995). For instance, Jenkins
and co-workers (Jenkins et al., 2004) have shown that phMRI
adequately assesses DA dysfunction, as dAMPH-induced
hemodynamic changes correlated well with loss of DAT
densities measured in 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP)-lesioned parkinsonian primates, using
PET. Interestingly, a recent imaging study showed a reduced
amphetamine-induced DA release in cocaine users (Martinez
et al., 2007). In addition several behavioral studies have linked
DAergic dysfunction to deﬁcits in attention, memory and
executive function (for review (Robbins and Arnsten, 2009)).
In this explorative study, we assessed brain monoamine
function in dAMPH users and comparison subjects, by
examining the hemodynamic response to an acute oral
challenge with methylphenidate (MPH). MPH is a DAT
blocker causing increased levels of synaptic DA, although
it also seems to have effects on norepinephrine (NE) levels,
by blocking also the NE transporter (NET) (Hannestad et al.,
2010; Volkow et al., 1998). We hypothesized that dAMPH
users would have lower striatal DAT binding levels thancontrols and a blunted hemodynamic response to MPH. We
also predicted that dAMPH users would show an altered




Participants underwent phMRI with an oral MPH challenge, followed
by [123I]FP-CIT SPECT scanning (to measure DATs) 1–3 weeks later. In
addition, neuropsychological tests and questionnaires were admi-
nistered on the day of the SPECT scan.
2.1.1. Subjects and study design
The medical ethics committee of the Academic Medical Center in
Amsterdam approved the study procedures. Participants were
recruited by advertising on the medical campus, websites and in
newspapers. They received a small ﬁnancial compensation of 50
euros per assessment day.
Eight male, recreational users of dAMPH and 10 male, healthy
control subjects (matched for age and IQ) participated. Written
informed consent was obtained from all subjects. The eligibility
criterion for the dAMPH group was previous use of dAMPH on more
than 40 occasions. The cut-off point was based on previous studies
from our group, where lower striatal DAT binding was found in
ecstasy users with combined dAMPH use (Reneman et al., 2002).
The control subjects were healthy subjects with no self-reported
prior use of dAMPH.
Subjects were asked to refrain from using caffeinated products
on assessment days. In addition, both controls and dAMPH users
agreed to abstain from all psychoactive drugs for at least 2 weeks
before scanning sessions. They underwent urine drug screening on
assessment days (with an enzyme-multiplied immunoassay for
amphetamines, cocaine, cannabis, alcohol, opiates and benzodia-
zepines). Exclusion criteria were: self-report of neuropsychiatric
diagnosis, history of brain disease or injury, use of medication
inﬂuencing the DAergic system (e.g., methylphenidate), a positive
urine-screen for amphetamines or any contra-indication to MRI.
2.1.2. Behavioral tests
The Dutch Adult Reading Task (DART) was used to estimate IQ
(Schmand et al., 1998). The DART is the Dutch counterpart of the
National Adult Reading Test (Nelson, 1982). It is relatively insensi-
tive to cognitive deterioration due to neurologic disorders and was
used to evaluate the premorbid IQ.
We selected ﬁve domains sensitive to DAergic function: execu-
tive function, attention, memory, mood and impulsivity. Tests were
administered in a mixed balanced order, with questionnaires
presented during the recall part of the RAVLT, to ascertain that
no other tasks of a verbal nature (e.g. DART) would interfere.
Executive function was measured using the trail making test.
Part A of this test (TMT-A), in which the subject draws lines
connecting consecutive numbers spread randomly on the page,
tests both visual scanning and motor speed (Reitan, 1956). Part B of
this test (TMT-B) alternates numbers with letters, focusing more on
executive function and visuomotor tracking. The ratio of times to
complete both parts of the test (TMT-B/TMT-A) was calculated to
assess executive function taking individual differences in visual
scanning and motor speed into account.
The sustained attention to response task (SART) displays numbers
one through nine randomly, followed by a mask and cue. The
subject needs to respond to the cue, except when the number three
appears (Bellgrove et al., 2005). The mask insures that speed-
accuracy trade-offs are of no major inﬂuence on the outcome.
Response variability was calculated (standard deviation go
1493Monoaminergic dysfunction in recreational users of dexamphetamineRT/ mean go RT) as well as the number of correct and incorrect
responses.
Verbal memory was assessed using the Rey Auditory Verbal
Learning Task (RAVLT (Rey, 1964)), in which subjects memorize 15
words in ﬁve learning trials. Following a 20-min delay, the word list
has to be recalled. Total scores were used for both direct and
delayed recall.
Mood and impulsivity were determined using validated ques-
tionnaires: the Beck Depression Inventory (BDI, (Beck, 1961)),
Behavioral Approach Scale (BAS, (Carver, 1994)) and Barratt Impul-
sivity Scale (BIS (Patton et al., 1995)). The BDI measures depression
severity, with higher scores indicating more severe depressive
symptoms. The BAS evaluates the behavioral approach system,
regulating an individual’s tendency to act on positive impulses. High
scores on the BAS tend to correlate with impulsive personalities(-
Carver, 1994). The BIS is aimed at motor impulsivity, cognitive
impulsivity and non-planning (Patton et al., 1995).
Finally, subjective emotional experience of MPH were measured
using simulated visual analog rating scales (VAS) 5 min before each
MRI scanning session. Subjects rated anxious feelings, tension,
feeling comfortable or uncomfortable, lightheadedness, wakeful-
ness, drowsiness and nausea on a scale of 1–10.
2.1.3. SPECT
Striatal DAT binding was measured using SPECTwith the radioligand
[123I]N-o-ﬂuoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)nortro-
pane ([123I]FP-CIT). [123I]FP-CIT is a well-validated radiotracer for
investigation of DAT availability, and was prepared as previously
described (Booij et al., 1998). Potassium iodide was used to block
thyroid uptake of free radioactive iodide. SPECT images were
acquired with a brain-dedicated SPECT system (Neurofocus, an
update of the Strichmann Medical Equipment 810X, Strichmann
Medical Equipment Inc., Medﬁeld, Mass., USA). This is a 12-detector
single-slice scanner with a full width at half maximum resolution of
6–7 mm. SPECT images were acquired as previously described (de
Win et al., 2005). Acquisition was commenced 3 h after i.v.
injection of approximately 112 MBq (3.02 mCi) [123I]FP-CIT, since
at this time peak speciﬁc binding to DATs in the striatum has been
reached (Booij et al., 1998).
2.1.4. SPECT processing
Reconstruction and attenuation correction of all images were
performed as previously described (Booij et al., 1997b). A striatum
ROI and separate ROIs for putamen and caudate nucleus were used,
which were positioned on the three consecutive SPECT slices
corresponding with the highest striatal activity. To correct for
background radioactivity (non-speciﬁc binding) a predeﬁned region
of interest (ROI) was placed over the occipital cortex. Finally,
speciﬁc to non-speciﬁc binding ratios were calculated (ROI
counts—occipital cortex counts/occipital cortex counts).
2.1.5. PhMRI
MR imaging was performed using a 3.0 T Philips MR scanner
equipped with an SENSE 8-channel head coil and body coil
transmission (Philips Medical Systems, Best, The Netherlands). The
protocol consisted of a high resolution 3DT1-weighted anatomical
scan for registration and segmentation purposes and a phMRI
sequence.
For the phMRI acquisition, we used a pulsed arterial spin labeling
(ASL) sequence, based on the PULSAR sequence (Golay et al., 2005).
ASL is a non-invasive perfusion imaging modality, using magnetically
labeled blood water protons as an endogenous tracer of CBF. Contrary
to the more traditionally used BOLD signal, the ASL signal does not
suffer from signal drifts in time, making it very suitable to investigate
pharmacologically-induced CBF changes (Wang et al., 2002).
phMRI imaging parameters were: TR/TE 3000/14 ms; FOV
240 240 mm2; matrix size 80 79; 17 slices; thickness 7 mm; nogap; gradient echo single shot EPI; SENSE 2.0; post-labeling delay
1.2 to 2 s; the labeling plane was positioned parallel to the imaging
volume with a labeling gap between the imaging volume and the
labeling volume of 25 mm. We acquired 100 dynamics (approxi-
mately 10 min of scanning time) at baseline and 100 dynamics 1.5 h
after administering 35 mg MPH, when it is assumed to be at its peak
concentration in the brain (Volkow et al., 1998). Methylphenidate
was obtained from Sandoz BV (Weesp, the Netherlands).
2.1.6. MR processing
FSL 4.1 (FMRIB-Software-Library, Functional Magnetic Resonance
Imaging of the Brain Centre, University of Oxford, UK), the SPM8
toolbox and Matlab (The MathWorks Inc., Natick, USA) were used for
ofﬂine data processing.
Subtraction of labeled and control ASL images yielded whole
brain perfusion weighted images. The mean equilibrium magnetiza-
tion (M0) of arterial blood per subject was calculated, from which
absolute CBF was computed following methods previously described
(Chalela et al., 2000). The images were averaged over 100 volumes
(10 min) to increase the signal-to-noise ratio (SNR), creating
average CBF maps from the baseline and post-challenge scans.
One scan from the dAMPH group was excluded due to poor image
quality. Average CBF maps were transformed into anatomical space
by afﬁne registration to the segmented gray matter masks of
corresponding anatomical scans.
3DT1 anatomical scans were segmented into gray and white
matter using SPM8. The structural images were non-rigidly
normalized to a population-based average using Diffeomorphic
Anatomical Registration Through Exponentiated Lie Algebra (DAR-
TEL) (Ashburner, 2007), to allow for a voxel-based analysis. The
non-rigid transformations were applied to the average CBF maps,
such that all dynamics of all subjects resided in one common frame
of reference. An isotropic resampling of 3.0 mm was chosen.
Finally, a Gaussian smoothing with FWHM=6 mm was applied to all
volumes. Mean perfusion was calculated for the following ROIs
taken from the Harvard–Oxford brain atlas provided with FSL 4.1:
striatum, prefrontal cortex (PFC), anterior cingulate cortex (ACC),
hippocampus, thalamus and cerebellum. The voxel-based analysis
was restricted to gray matter, where the CBF can be sufﬁciently
precisely measured, by means of a mask.
2.2. Statistical analysis
Continuous variables of group characteristics were analyzed using
unpaired two-tailed Student’s t-tests (log transformed if necessary)
and Mann-Whitney tests for drug history variables. Differences in
behavioral measures between the two groups on the ﬁve cognitive
domains were analyzed using multivariate analysis of variance
(MANOVA). To limit the number of statistical comparisons per group,
TMT and RAVLT were grouped and SART was analyzed in a separate
MANOVA as well as results for mood and impulsivity questionnaires.
Striatal DAT binding ratios measured with SPECT for whole striatum
and putamen and caudate nucleus separately were analyzed using
the Mann-Whitney test.
PhMRI data was analyzed by calculating the effect of challenge
through paired t-testing between baseline and post-challenge scans
for both groups separately. Both a ROI-based and a voxel-based
analysis were performed. Thus, in the ROI-based analysis we ﬁrst
compared group baseline differences in CBF, followed by comparing
baseline with post-MPH scans using paired t-test for both groups
separately, and ﬁnally unpaired t-tests to compare the percentage
CBF change between the two groups. In the voxel-based analysis, a
minimal cluster size of 100 voxels was maintained, besides a
signiﬁcance threshold of p=0.01. Also in the voxel based analysis,
baseline differences and response to the challenge were examined,
as well as an interaction analysis to determine any difference in
response to MPH between groups.
M.L.J. Schouw et al.1494Finally, correlations were calculated between DAT binding ratios
and percentage CBF change in the striatum, and between signiﬁ-
cantly differing behavioral measurements and percentage CBF
change.
All data were analyzed in SPSS version 18.0 (SPSS Inc, Chicago,
Ill) and are presented as mean7SD unless otherwise indicated.
3. Results
3.1. Characteristics of the sample and behavioral
measures
Group characteristics are presented in Table 1. Age, pre-
morbid IQ and years of education were similar in both
groups. Mean cumulative lifetime exposure to dAMPH was
353 g (7465, range of use 0.5–3 g per occasion) and time
since last dose on average 1.1 (71.3) months. dAMPH users
had on average used more other recreational drugs of abuse
and tobacco than the control subjects.
The behavioral scores on the ﬁve DAergic domains
(attention, executive control, memory, mood and impulsiv-
ity) are shown in Table 2. A signiﬁcant main effect was
revealed on MANOVA of executive function and memory.
dAMPH users were signiﬁcantly slower on TMT-B/TMT-A
when compared to controls. dAMPH users were also slower
on TMT-A, but this did not reach statistical signiﬁcance
(p=0.06). Both on the immediate and delayed verbal
learning task, dAMPH users recalled less words than the
control subjects, reaching statistical signiﬁcance only for
the delayed recall. Mean group scores for attention, mood
and impulsivity (SART, BDI, BAS and BIS scales) did not differ
between groups.
Before the MPH challenge, no differences were noted
on the VAS scores between dAMPH users and healthy
controls. However, after the challenge, control subjectsTable 1 Demographics characteristics of drug exposure for dA





Years of education 15.1 (7
dAMPH
Average dAMPH use (occasions/year) 27.8 (7
Duration of dAMPH use (years) 13.9 (7
Usual dose (grams/occasion) 0.8 (7
Total exposure (grams) 352.6 (7
Time since last exposure (months) 1.1 (7
Other substances
Average tobacco use (cigarettes/month) 261.0 (7
Average alcohol use (units/month) 103.5 (7
Average cannabis use (joints/year) 410.3 (7
Average MDMA use (pills/year) 3.8 (7
Average cocaine use (occasions/year) 5.0 (7
NA=Not applicable.
nnDrug history questionnaire missing for 1 control subject.felt signiﬁcantly less sleepy (0.971.0; p=0.02) and more
lightheaded (1.771.7; p=0.01), in contrast to dAMPH users
who did not show such an effect. When comparing the
change in VAS scores, there was no signiﬁcant difference on
any of the subjective measures between the groups.
No signiﬁcant correlations were observed between the
TMT-B/TMT-A ratio and percentage CBF change in the PFC
(linked mainly to executive functions), nor between the
delayed recall and the percentage CBF change in the
hippocampus (linked mainly to memory).
3.2. SPECT
No differences in binding between left and right hemi-
spheres were detected, therefore we present grouped data.
Binding ratios did not differ signiﬁcantly between dAMPH
users and healthy controls. However, all ROIs studied (whole
striatum, caudate nucleus and putamen) showed 8.4–10.4%
lower binding ratios (Fig. 1) in dAMPH users and a trend was
seen for the whole striatum and putamen (p=0.06 and
p=0.05, respectively). When comparing only non-smoking
subjects (healthy controls n=8; dAMPH n=3) no signiﬁcant
differences in striatal DAT binding ratios were observed
between the groups. No signiﬁcant correlations were
observed between DAT binding ratios and the percentage
CBF change in the striatum.
3.3. 3 phMRI
3.3.1. Pre MPH CBF measures: ROI and voxel based
analysis
ROI analysis did not show any signiﬁcant differences in
baseline CBF measurements between dAMPH users and
healthy controls. Voxel-based analysis, however, showedMPH users and controls with (7SD) and p-values for t-test
cant p-values (o0.05) marked with.
sers Controls
n=10 p-value
4.0) 23.0 (73.8) 0.1
3.0) 108.3 (76.4) 0.1






279.8) 0.4 (71.3) 0.02
146.6) 101.8 (778.6) 0.4
480.5) 17.2 (730.4) 0.02
10.6) 0 0.3
5.2) 0.1 (70.3) 0.006
Table 2 Behavioral measures all measures reﬂected are averaged means (7 standard deviation). p-values were obtained
using MANOVA. NS= not signiﬁcant; p= p-value; F= F-value; ES= Effect size (cohen’s d).
Controls n=10 dAMPH n=8 p F ES
MANOVA-group 0.02
Executive function
TMT-A (seconds) 16.7 (72.9) 23.4 (79.5) 0.06 4.17 1.08
Ratio TMT-B/TMT-A 1.91 (70.2) 2.65 (70.8) 0.04 4.82 1.48
Memory function
RAVLT immediate 52.8 (78.4) 43.8 (78.6) 0.10 3.07 1.06
RAVLT delayed 11.8 (72.6) 9.5 (72.7) 0.02 6.94 0.87
MANOVA-group NS
Attention
SART correct go RT (milliseconds) 132.3 (748.9) 174.3 (735.6) 0.99
SART response variability 0.50 (70.1) 0.39 (70.07) 1.29
SART incorrect go (number of trials) 21.6 (715.7) 10.0 (710.2) 0.90
SART incorrect nogo (number of trials) 2.3 (73.3) 2.6 (73.0) 0.10
MANOVA-group NS
Mood
BDI 1.6 (72.7) 3.3 (71.8) 0.76
Impulsivity
BIS 62.4 (78.7) 66.3 (78.4) 0.46
BAS 26.8 (73.3) 30.0 (75.3) 0.74
nNeuropsychological data for one control subject was not available.
nnTwo control and one dAMPH data set from the SART had to be excluded due to poor performance (425% missed go trials).
Fig. 1 DAT binding ratios in the putamen, caudate nucleus and
whole striatum of dAMPH users and healthy controls. Although
dAMPH users showed lower binding ratios, no statistical sig-
niﬁcance was observed between groups. Error bars reﬂect
standard deviation.
1495Monoaminergic dysfunction in recreational users of dexamphetaminethat baseline CBF was higher in the left thalamus (peak
level Z=3.48, po0.0001, uncorrected) and insula (peak
level Z=3.61, p=0.000, uncorrected) of dAMPH users com-
pared to healthy controls (Fig. 2).3.3.2. Post MPH CBF measures
3.3.2.1. ROI-based analysis. The oral challenge with MPH
caused an overall reduction in gray matter CBF of 15.8%
in control subjects (Fig. 3). In contrast, in dAMPH users MPH
did not induce any changes in CBF: a non-signiﬁcant
increase of 1.0% was observed. In several ROIs in control
subjects we observed a signiﬁcant reduction in CBF: the
striatum—9.6%, hippocampus—28.1%, thalamus—28.1%
and PFC—11.6%. In dAMPH users we observed a signiﬁcant
decrease of CBF in the hippocampus of—21.0%. The average
CBF and p-values are represented in Table 3.
We also examined the group difference in response to
MPH using unpaired t-testing in the percentage CBF change.
A signiﬁcant interaction effect was observed in the thala-
mus: healthy controls showed a decrease of 28.1% where
dAMPH users showed an increase in CBF of on average 34.9%
(p=0.03).
3.3.2.2. Voxel-based analysis. When examining the data
using a voxel-based approach, several brain areas in healthy
controls showed statistically signiﬁcant decreases in CBF
(Fig. 4a). In agreement with the ROI based analysis, the
striatum, thalamus, hippocampus and PFC showed a reduc-
tion in CBF following an acute challenge with MPH in control
subjects with the most signiﬁcant cluster located in the
right striatum (peak level Z=4.92, p=0.000). The voxel-
based analysis identiﬁed additional regions to the ROI based
analysis in which MPH induced a reduction in CBF: the
Fig. 2 Statistical parametric map of baseline CBF differences between healthy controls and users of dAMPH. Color bars indicate
z-scores of areas where CBF is larger in dAMPH users compared to controls. Lower CBF values were not observed. Statistic images
were thresholded to a cluster signiﬁcance threshold of p=0.01 with a minimum cluster size of 100.
M.L.J. Schouw et al.1496insula, the sensorimotor and visual cortex. In the group of
dAMPH users we only observed a signiﬁcant decrease in CBF
in the hippocampus (similar to the ROI based analysis) and in
the (orbitofrontal) PFC (Fig. 4b). In the healthy controls, a
small area of the orbitofrontal cortex demonstrated an
increase in CBF (Fig. 4c). In dAMPH users no increases in
CBF were seen in response to the MPH challenge. When
examining the interaction effect of group  challenge
(Fig. 4d), the main difference in response between the
groups is located in the (left) thalamus (peak level Z=3.29,
p=0.000).
4. Discussion
The results of this study show that several indices of
monoaminergic function in recreational dAMPH users differ
from those in healthy controls. In addition to a blunted
hemodynamic response to a challenge with MPH in DAergic
brain regions, we found a trend toward reduced DAT binding
in the striatum. Finally, dAMPH users showed impaired
performance on executive function and memory.
4.1. Baseline behavioral measures
DA function in the PFC in particular is linked to cognitive
processes, where DA cells connecting the PFC to several limbic
structures, including the amygdala, nucleus accumbens andhippocampus, have a regulatory role in several cognitive
processes (de Almeida et al., 2008). In view of our hypothesis
on DA dysfunction in dAMPH it is therefore not surprising that
we observed impaired functions in two cognitive domains
mediated by the mesocortical pathways (DAergic projections
from the ventral tegmental area to the cortex, particularly
the PFC) and mesolimbic pathways (projections from the
ventral tegmental area to the limbic system and PFC) of
dAMPH users, namely: executive functioning and memory
consolidation. Our ﬁndings of frontal-executive dysfunction
in dAMPH users are in agreement with a study by Ornstein
(Ornstein et al., 2000). Furthermore, previous studies have
shown impaired memory function in users of this drug
(Leventhal et al., 2010; Rapeli et al., 2005).4.1.1. Post MPH behavioral measures
Only control subjects showed a small increase in light-
headedness and decreased sleepiness in response to the
MPH administration, although there was no interaction
effect between the groups. Our ﬁndings are in line with
other studies that show that even doses as small as 20 mg of
MPH can elicit signiﬁcant changes in measures of subjective
drug effect, such as ratings for ‘feel an effect’ and ‘like the
drug effect’ (Spencer et al., 2006). Interestingly, the
absence of an effect of MPH on the VAS score in dAMPH
users is in agreement with the decidedly blunted effect of
1497Monoaminergic dysfunction in recreational users of dexamphetamineMPH on CBF. This may reﬂect monoaminergic dysfunction in
dAMPH users.4.2. Baseline imaging data
4.2.1. SPECT
Although we found no statistically signiﬁcant difference
in striatal DAT binding when comparing the groups, a trend
toward a lower binding (approximately 10%) was observed in
the putamen and striatum as a whole. Previous studies
showed a relative high inter-individual variation in striatal
DAT binding (Booij et al., 2007; Ziebell et al., 2010).
Consequently, due to the small sample examined, we canFig. 3 Mean CBF (ml/100 g/min) in the total gray matter and
predeﬁned ROIs before MPH (light gray bars on the left) and
after ingestion of 35 mg of MPH (dark gray bars on the right) for
control subjects (upper panel) and dAMPH users (lower panel)
separately. Error bars reﬂect standard deviation. : statisti-
cally signiﬁcant differences between conditions.
Table 3 CBF measurements average CBF (ml/100 g/min) per R









Gray matter 49.2 (715.0) 39.4 (76.4) 0.022 0.92
Striatum 42.6 (711.7) 37.8 (78.2) 0.049 0.48
Hippocampus 77.7 (740.0) 51.4 (722.6) 0.003 0.84
Thalamus 54.4 (728.2) 34.6 (711.5) 0.022 1.00
PFC 40.5 (711.1) 34.8 (77.4) 0.035 0.62
ACC 73.3 (719.3) 65.6 (713.2) 0.144 0.47
Cerebellum 51.6 (732.8) 35.9 (79.5) 0.094 0.74not exclude that the trend for a lower striatal DAT binding in
our dAMPH users in fact reﬂects this variation. Also,
although the radiotracer [123I]FP-CIT binds with high afﬁnity
to the DAT, it binds also with a lower, but still moderate,
afﬁnity to serotonin transporters (Booij et al., 1997a;
Ziebell et al., 2010). Therefore, we cannot exclude that
the lower striatal [123I]FP-CIT binding in dAMPH users
reﬂects changes in serotonin transporter expression. How-
ever, in a previous study in healthy controls we showed that
oral administration of the selective serotonin transporter
inhibitor paroxetine did not induce a signiﬁcant lower
striatal [123I]FP-CIT binding (Booij et al., 1997a). In addi-
tion, PET studies in dAMPH-treated vervet monkeys have
shown reductions in striatal [18F]DOPA uptake (a marker of
the integrity of, and synthesis of DA in, nigrostriatal DAergic
neurons) (Melega et al., 1996). Furthermore, studies in
rodents, cats and non-human primates have shown that
chronic dAMPH exposure results in neurotoxicity character-
ized by decreases in DA levels and DAT and DA receptor
densities, swollen nerve terminals and degenerated axons
(Ginovart et al., 2004; Ricaurte et al., 2005). Indeed, we
have previously observed 20% lower striatal DAT binding in a
group of combined MDMA (ecstasy) and dAMPH users that
had used approximately twice the amount of dAMPH life-
time (Reneman et al., 2002). Given the large body of
evidence directly documenting the DA neurotoxic potential
of dAMPH in rodents and nonhuman primates (reviewed in
(Berman et al., 2008)), in this explorative study we provide
preliminary evidence that recreational use of dAMPH might
lead to loss of DA neurons. Besides neurotoxicity, neuro-
plastic alterations of monoaminergic neurons related to
associative drug conditioning or to non-associative drug
sensitization have also been described (Singer et al.,
2009). Indeed, neuroplasticity related to the formation of
addiction can give rise to both an increase and decrease in
dendritic spine formation (reviewed in (Nestler, 2001)).
Probably a combination of both neurotoxic and neuroplastic
effects has led to the presently observed lower DAT binding
ratios in this group of AMPH users.4.3. Pre MPH CBF measures
Our voxel-based analysis showed a higher CBF in the left
thalamus of dAMPH users. It has been previously demon-
strated that higher DAT availability correlates with lowerOI per group (7SD). Light gray marking reﬂects signiﬁcant









54.8 (710.6) 54.6 (713.7) 0.969 0.02
44.3 (77.6) 42.7 (710.8) 0.604 0.17
67.7 (717.9) 53.1 (718.4) 0.026 0.80
52.0 (723.2) 55.8 (713.9) 0.729 0.21
43.6 (78.8) 40.7 (79.9) 0.148 0.31
88.9 (718.2) 84.2 (724.4) 0.320 0.22
62.0 (730.8) 62.6 (729.5) 0.966 0.02
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observed in dAMPH users may be linked to the lower DAT
availability we observed. Because this increased CBF is a
unilateral ﬁnding and results were not conﬁrmed in the ROI-
based analysis, this data should be interpreted with caution
and needs to be replicated in larger groups. Also, the
CBF measurements had considerable intra-subject variabil-
ity. However, ASL has been found to be very consistent
across time and scanners and our mean CBF values
and variability are in accordance with previous studies
(Gevers et al., 2011).Fig. 4 Statistical parametric map of CBF change induced by
hippocampus, prefrontal cortex, insula, motor cortex and visua
(B) Decreased CBF in several areas of the PFC and a small part of
(C) Increased CBF in healthy controls in the orbitofrontal cortex a
response to the MPH challenge differs between healthy controls and
thresholded to a cluster signiﬁcance threshold of p=0.01 with a mi4.4. Post MPH imaging data
4.4.1. In healthy subjects
After administering MPH to healthy subjects, we noted
marked changes in CBF in several key DAergic signaling
regions: striatum, thalamus, PFC and hippocampus, in
addition to the visual and sensorimotor cortex. All these
regions, apart from the visual cortex, are rich in DAergic
neurons (Missale et al., 1998). In particular, the striatum
and PFC are thought to be inﬂuenced by MPH’s effect on
dopaminergic signaling. For example, Volkow and colleagues35 mg MPH. (A) Decreased CBF in the striatum, thalamus,
l cortex of healthy controls in response to the challenge.
the hippocampus in dAMPH users in response to the challenge.
nd (D) Interaction effect. Clusters reﬂect the areas where the
dAMPH users. Color bars indicate z-scores. Statistic images were
nimum cluster size of 100.
1499Monoaminergic dysfunction in recreational users of dexamphetaminedemonstrated a decrease in metabolism in the basal ganglia
in response to MPH in all subjects and an increase in PFC
metabolism, similar to our results, in subjects with high D2
receptor availability (Volkow et al., 1997). Several task
related fMRI studies also demonstrated decreased activity in
the striatum in response to MPH in healthy subjects,
whereas it has been shown to increase brain activation in
ADHD patients (Rohde et al., 2003; Vaidya et al., 1998).
Wang et al. found a more generalized decrease in CBF,
including the striatum, using [15O]H2O PET, and attributed
this to the vasoactive properties of MPH (Wang et al., 1994).
However, a smaller i.v. dose (0.25 mg/kg) showed regional
decreases in CBF, in the ACC, temporal poles and supple-
mentary motor cortex, similar to our results (Udo de Haes
et al., 2007). It has previously been demonstrated that the
cardiovascular properties of MPH do not alter neuronal
hemodynamic coupling. Rao and co-workers observed no
effect of oral MPH on a ﬁnger tapping task, although heart-
rate gradually increased following MPH challenge (Rao
et al., 2000). This, taken together with our ﬁndings of CBF
changes in brain regions commonly linked to DAergic func-
tion, strongly suggests that our ﬁndings are linked to
DA neuronal function rather than reﬂecting a vascular
response.
Besides increasing levels of DA in the striatum, micro-
dialysis studies have shown that MPH increases extracellular
NE levels in the hippocampus (Kuczenski and Segal, 1997).
Indeed, MPH has been shown to be a very potent inhibitor of
DAT and NET (KI=0.06 mM and 0.10 mM), whereas it is not a
potent inhibitor of SERT (KI=132 mM) (Han and Gu, 2006).
We therefore cannot exclude that increased NE levels
contributed to the decrease in CBF we observed in response
to MPH in the thalamus and hippocampus, whereas this is
unlikely to be the case for 5-HT levels. However, since
striatal increases in NE are less pronounced in comparison to
that of DA (Koda et al., 2010), the results we observed are
likely mainly attributable to an attenuation of DAergic
signaling.4.4.2. In dAMPH users
It has been previously suggested that the hemodynamic
response to increased metabolic demand caused by a
pharmacological challenge can be an indirect measure of
DA release: there is a tight correlation between hemody-
namic changes induced by dAMPH and extracellular DA
measurements obtained by microdialysis in rats (Chen
et al., 1997; Chen et al., 1999). In addition, in non-human
primates the extent of the hemodynamic response corre-
lated well with PET markers of DA cell loss (Jenkins et al.,
2004). Also, MPH-induced metabolic changes correlate with
differences in DA D2 receptor binding and dAMPH has been
found to signiﬁcantly decrease D2 receptor availability in
rats (Ginovart et al., 2004). It is therefore likely that the
blunted response to the challenge with MPH in dAMPH users
reﬂects DA dysfunction. dAMPH users only showed a
decrease in CBF in a small area of the hippocampus and
the medial PFC (mPFC). As mentioned before, Volkow and
colleagues found a difference in response to MPH in the PFC
depending on D2 receptor availability (Volkow et al., 1997).
In line with this, Gulley and co-workers demonstrated with
single cell recordings in rats that neuronal ﬁring in theentire PFC increased after the ﬁrst injection with dAMPH
(Gulley and Stanis, 2010). This effect diminished after
repeated dAMPH administrations, apart from the mPFC
which increased its ﬁring rate. Indeed, Volkow and collea-
gues (Volkow et al., 2005) saw a similar difference in
metabolic rate in response to MPH in the mPFC of cocaine
addicts compared to healthy controls. The fact that we
observed a blunted response to MPH on a behavioral level
(VAS scores), as well as in brain hemodynamics (CBF) in
dAMPH users, coupled with the ﬁndings in the PFC, leads to
the hypothesis that the mPFC may be particularly sensitive
to repeated exposure to this drug.
We also found a difference in baseline CBF and response
to the challenge in the thalamus using both a ROI based and
a voxel-based approach. Oral dAMPH has been shown to lead
to increased CBF in the PFC and anterior thalamus in
healthy controls (Devous et al., 2001) and subjects detox-
iﬁed from METH use (a drug very similar to dAMPH), were
found to have a lower metabolism located predominantly in
the thalamus and to a lesser extent the striatum (Volkow
et al., 2001). What remains to be elucidated is whether
these thalamic changes are an indirect effect of altered
cortico-striato-thalamic signaling as suggested by Honey and
colleagues (Honey et al., 2003) or whether repeated dAMPH
exposure has a direct inﬂuence on thalamic function and
integrity.4.5. Limitations
Here we show a blunted CBF response in dAMPH users to a
monoaminergic challenge using several (imaging) techni-
ques. However, there are several limitations to this study
that should be mentioned. We designed the study as an
explorative study, involving a limited number of subjects.
Because interindividual differences may be considerable,
this could have affected the reliability of our measure-
ments. Also, although we tried to match groups as much as
possible on both age and IQ, the matching was not perfect.
Additional analysis of covariance including age and IQ
measures, showed that DAT binding ratios were not inﬂu-
enced by these two factors (p=0.07 overall effect of group;
a scatterplot of DAT binding and age is provided as
supplementary material). Interaction effects in the voxel-
based analysis of CBF did not notably change when adding
these covariates. DAT binding may be affected by including
smoking and cannabis use (Leroy et al., 2012), however
again the voxel-based interaction showed similar activation
patterns when including the covariates. Nevertheless, the
data should be interpreted as such and needs to be
conﬁrmed in a larger sample.
Also, the presently observed difference in response could
be due to other drugs than dAMPH. However, because other
drugs were used only occasionally, whereas dAMPH was used
on a regular basis, it is unlikely that the ﬁndings of the
present study should be attributed to substances other than
dAMPH. In addition, the SPECT scan was performed after the
ﬁrst MPH challenge, which may have led to sensitization of
the DAergic system. However, to our knowledge alterations
in DAT binding ratios have not been described after a single
dose of MPH.
M.L.J. Schouw et al.1500Because subjects had to abstain for two weeks from
psychoactive drugs, it is unlikely that results are inﬂuence
by effects of dAMPH or other drugs (other than MPH that
was administered during the study). Other than self-report
and urine screening on testing days, we were not able to
ensure abstention from dAMPH. However, a survey in The
Netherlands investigated showed that in 93% of the cases
(n=594) the reported drug use was in agreement with
the drug-urine test (Addiction Research Institute 1998). In
future studies, hair sample analysis would be a useful way to
ascertain previous use of dAMPH.
As with all retrospective studies, there is a possibility
that pre-existing differences between dAMPH users and
controls underlie differences in DA functioning. Also, we
cannot completely exclude the presence of psychiatric
disease, such as ADHD, in our dAMPH group although we
excluded participants with (a history of ) any psychiatric
condition. Only a prospective study in users with a high risk
of starting to use dAMPH, with an extensive psychiatric
assessment, as we previously conducted for MDMA (de Win
et al., 2008), can solve this issue.
4.6. Conclusions
The results of this study show that use of dAMPH at
recreational doses leads to DA dysfunction, as evidenced
by: (a) functional impairments on neuropsychological mea-
sures sensitive to DA function (b) a clear trend toward
reductions in DATs in the striatum, and (c) a blunted
hemodynamic response to a challenge with MPH in several
brain regions rich in DA. Future (prospective) studies in
larger groups of dAMPH users should be conducted to
conﬁrm our preliminary ﬁndings. Our results also provide
evidence that phMRI may be a sensitive tool in imaging DA
dysfunction in humans non-invasively using an oral
challenge.
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